What does this research mean for the field?

TGD001, a novel von Willebrand factor-targeting thrombolytic, effectively degrades human acute ischemic stroke thrombi ex vivo and demonstrates a favorable safety and pharmacological profile in healthy volunteers. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to evaluate the efficacy and safety of TGD001, a novel thrombolytic targeting VWF, in ex-vivo models and healthy volunteers.

May 8, 2026European Stroke JournalOpen Access

Abstract Number: Esoc2026a1328 Tgd001, a Novel VWF-Targeting Thrombolytic, Effectively Degrades Ex-Vivo Human Stroke Thrombi and Demonstrates Safety and Activity in a Phase 1 Healthy Volunteer Trial

View Full Paper

Ask AI

Bookmark

Authors

MHMarielle Klein HesselinkLinXis Biopharmaceuticals (Netherlands)SMSteven de MaatLinXis Biopharmaceuticals (Netherlands)SFSarah Mc FieLinXis Biopharmaceuticals (Netherlands)

Discussion

Member takes

Implication

Randomized trial assesses TGD001's thrombolytic activity in healthy volunteers, indicating potential for acute ischaemic stroke treatment.

Key Points

This research aims to evaluate the efficacy and safety of TGD001, a novel thrombolytic targeting VWF, in ex-vivo models and healthy volunteers.
Ex-vivo thrombolysis using human thrombi from acute ischaemic stroke patients.
Assessment of TGD001's performance in ROTEM assays with healthy donor plasma.
Phase 1 trial involving 34 healthy male participants across four dose cohorts.
TGD001 effectively lysed ex-vivo human AIS thrombi with a high correlation to VWF content (r = 0.903; P < 0.01).
Induced dose-dependent thrombolysis in ROTEM assays without affecting thrombus formation.
No dose-limiting events or spontaneous bleeding observed; TGD001's half-life ranged from 2 to 8 hours.

Cite This Study

Hesselink et al. (2026) studied this question.

synapsesocial.com/papers/69fd7fcdbfa21ec5bbf085a2 https://doi.org/10.1093/esj/aakag023.085

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial assesses TGD001's thrombolytic activity in healthy volunteers, indicating potential for acute ischaemic stroke treatment.

Abstract Number: Esoc2026a1328 Tgd001, a Novel VWF-Targeting Thrombolytic, Effectively Degrades Ex-Vivo Human Stroke Thrombi and Demonstrates Safety and Activity in a Phase 1 Healthy Volunteer Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract Number: Esoc2026a1328 Tgd001, a Novel VWF-Targeting Thrombolytic, Effectively Degrades Ex-Vivo Human Stroke Thrombi and Demonstrates Safety and Activity in a Phase 1 Healthy Volunteer Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider